e-learning
resources
Amsterdam 2015
Monday, 28.09.2015
Screening strategies in TB
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons
Elmira Gurbanova (Baku, Azerbaijan), Elmira Gurbanova, Rafail Mehdiyev, Kai Blondal, Alan Altraja
Source:
International Congress 2015 – Screening strategies in TB
Session:
Screening strategies in TB
Session type:
Poster Discussion
Number:
2984
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Elmira Gurbanova (Baku, Azerbaijan), Elmira Gurbanova, Rafail Mehdiyev, Kai Blondal, Alan Altraja. High prevalence of hepatitis C among patients with drug-resistant tuberculosis and its impact on the treatment outcome in Azerbaijan prisons. Eur Respir J 2015; 46: Suppl. 59, 2984
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Debate -Tuberculosis: Rolling out of new drugs without diagnostic capacities
Panel discussion on unprecedented progress in shortening treatment for TB: Evidence to date, and future possibilities
Related content which might interest you:
The incidence of MDR-TB in new and retreatment cases of HIV and pulmonary tuberculosis co-infection
Source: Annual Congress 2013 –Tuberculosis: clinical aspects
Year: 2013
Prevalence and trend of ofloxacin-resistance among MDR-TB including XDR-TB cases in Ukraine
Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children
Year: 2015
Prevalence of latent tuberculosis infection among household contacts and community controls in South India
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection: diagnosis and treatment
Year: 2013
Increased incidence of TB disease within the health-care workers in an intermediate TB burden country
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Characteristics of tuberculosis (TB) in patients that died from TB in Poland
Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis
Year: 2016
Knowledge and attitude about tuberculosis disease in a health workers population
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I
Year: 2013
MDR-TB treatment outcomes in HIV positive patients
Source: International Congress 2014 – Tuberculosis: from diagnosis to therapy and prevention
Year: 2014
Impact of social support programme on MDR-TB patients' treatment outcomes
Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3
Year: 2014
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia)
Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes
Year: 2015
HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs
Source: International Congress 2015 – TB treatment: new drugs and drug resistance
Year: 2015
Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Programmatic management of drug resistance tuberculosis: Outcome analysis of 200 patients in western part of Rajasthan, India
Source: International Congress 2016 – Update on drug-resistant tuberculosis
Year: 2016
Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai
Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis
Year: 2016
Screening immigrants to Ireland from countries with a high prevalence of tuberculosis would be clinically beneficial and cost effective
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations
Year: 2013
The health economics of treating MDR-TB in the Indian private sector
Source: International Congress 2016 – How the increasing complexity of chronic care management challenges ethics and costs in our healthcare system
Year: 2016
Multidrug-resistant and extensively drug resistance tuberculosis has a strong public health and economical impact in the Republic of Moldova
Source: Annual Congress 2013 –Tuberculosis and latent tuberculosis infection in subpopulations
Year: 2013
Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine
Source: Annual Congress 2013 –Drug-resistant tuberculosis
Year: 2013
Trend in TB control in Republic of Moldova: High MDRTB burden country
Source: International Congress 2014 – Tuberculosis: epidemiology and public health
Year: 2014
Impact and management of TB childhood outbreaks in EU/EEA
Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis
Year: 2013
Changing prevalence of MDR TB and XDR TB in a tertiary care hospital in India
Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I
Year: 2013
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept